Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20089 + adebrelimab
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HS-20089 + adebrelimab is a combination regimen under clinical development for advanced solid tumors. HS-20089 is an antibody-drug conjugate (ADC) consisting of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a protease-cleavable linker. It targets B7-H4, an immune checkpoint glycoprotein overexpressed in ovarian and endometrial cancers. Adebrelimab is a fully humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), enhancing anti-tumor immune response by blocking the interaction of PD-L1 with PD-1 and B7-1. The combination seeks to leverage targeted cytotoxicity by HS-20089 and immune activation by adebrelimab for synergistic anti-tumor activity. Developed and investigated primarily for advanced or recurrent gynecological and other solid tumors, including ovarian and endometrial cancers[1][2][3][5].
- Brand names
- Atridia
- Other names
- HS-20089 + adebrelimab
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)TOP1 (DNA Topoisomerase I)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on HS-20089 + adebrelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20089 + adebrelimab.